The genetic basis of inhibitor development in haemophilia A
| Autor: | C. A. Lee, C. M. Kessler, D. Varon, U. Martinowitz, M. Heim, E. G. D. TUDDENHAM, J. H. MCVEY |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Haemophilia A
Haemophilia medicine.disease_cause Hemophilia A Antibodies Immune system Antigen Immunity HLA Antigens hemic and lymphatic diseases medicine Humans Genetics (clinical) Mutation Factor VIII biology business.industry Haplotype Hematology General Medicine medicine.disease Virology Haplotypes Immunology biology.protein Antibody business |
| Zdroj: | Haemophilia : the official journal of the World Federation of Hemophilia. 4(4) |
| ISSN: | 1351-8216 |
| Popis: | Inhibitor development is now the main complication of replacement therapy in haemophilia A. Given that most severely affected patients make no detectable factor VIII, it is perhaps surprising that only approximately 30% actually mount an immune response to factor VIII as a foreign antigen. Those that do mostly have major factor VIII gene lesions. The association of HLA genotype with inhibitors in patients with identical mutations is weak. Environmental factors may be more important than genetic in antibody response to factor VIII. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text